Seer Surpasses 100 Peer-Reviewed Publications in Proteomics Research

REDWOOD CITY, Calif., Sept. 16, 2026 /CourierPR/ -- Seer, Inc., a pioneer in deep, unbiased proteomics, has reached a significant milestone with its Proteograph® Product Suite being used in over 100 peer-reviewed scientific publications. This achievement underscores the company’s commitment to advancing proteomics research at scale and highlights the impact of its innovative technology on the scientific community.

Founded to address the longstanding tradeoff in proteomics research, wherein deep, unbiased analysis was traditionally limited to small sample sizes, while large-scale studies often lacked the depth of information, Seer’s Proteograph Product Suite combines engineered nanoparticles with mass spectrometry. This integration enables researchers to access deep, unbiased proteomic information across large studies with the throughput, reproducibility, and economics required for population-scale research.

The company’s technology has been applied in a diverse range of studies, spanning genetics, aging, disease biology, biomarker discovery, and population health. Notable among these are publications in prestigious journals such as Nature, Nature Medicine, Nature Genetics, and Nature Aging. For instance, a study published in Nature Genetics by Claudia Langenberg, M.D., Ph.D., and collaborators at Queen Mary University of London and the Berlin Institute of Health at Charité, used the Proteograph Product Suite to profile more than 1,400 British South Asian participants. The study identified over 3,430 proteins not covered by leading affinity-based platforms and more than 1,200 genetic associations with plasma proteins, many of which had not been previously reported.

Another significant study, published in Nature Genetics, involved researchers from Harvard Medical School/Brigham and Women’s Hospital and TruDiagnostic. They used Proteograph to perform large-scale, peptide-level mass spectrometry proteomics across approximately 1,600 samples. This approach allowed the researchers to distinguish between true changes in protein biology and changes in binder recognition caused by protein-altering variants, providing a more accurate path from genetics to drug targets and biomarkers.

In a study published in Nature Aging, Nathan Basisty, Ph.D., and colleagues used Proteograph to deeply characterize the proteins secreted by senescent human monocytes and connect those signatures to plasma measurements from over 1,000 participants in the Baltimore Longitudinal Study of Aging. The study identified circulating senescence-associated proteins linked to multiple age- and obesity-related clinical traits, demonstrating the potential of deep proteomics to translate cellular mechanisms of aging into measurable signals in humans.

Seer’s technology has been instrumental in unlocking substantial new biological insights, connecting genetic variation to proteins and disease, and extracting far more information from valuable cohorts.

The body of work, which includes studies published in high-impact journals, marks a significant milestone in the emergence of deep proteomics at scale as a new paradigm for biological research. As Seer continues to advance its technology, it is well-positioned to support the growing demand for deep, reproducible, and information-rich human data, particularly in the age of artificial intelligence.